曾拿到国内biotech最好开局的荣昌生物,如今的牌越打越不顺。3月28日,荣昌生物发布公告称,2024年公司实现营业收入17.17亿元,比去年同期增长57.54%,但公司依然处于亏损,2024年净亏损达14.68亿元。荣昌生物向外界表示:目前亏损趋势已开始扭转,同比缩小2.84%。目前,荣昌生物在手现金及等价物约10亿元,不够亏一年,2025年肯定要用到其他短期融资途径。公司方面也说:可用贷款...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.